SPY315.20-1.86 -0.59%
DIA260.36-2.64 -1.00%
IXIC10,401.28-32.37 -0.31%

Rubius Therapeutics Says Has Completed Dosing Of First Dose-Escalatoin Cohort With No Observed Adverse Events To Date In Phase 1/2 Trial Of RTX-240

Benzinga · -